CHEK1: Checkpoint Kinase 1 - DNA Damage Response Regulator

A key serine/threonine kinase in cell cycle checkpoint control and genomic stability

Gene Information Card

Symbol CHEK1
Full Name Checkpoint Kinase 1
Gene Type Protein coding
Chromosomal Location 11q24.2
NCBI Gene ID 1111 ncbi.nlm.nih.gov/gene/1111
Ensembl ID ENSG00000149554
UniProt ID O14757
OMIM ID 603078
HGNC ID 1925
Aliases CHK1, CHEK1, CHK1 checkpoint homolog

Description

CHEK1 (Checkpoint Kinase 1) encodes a serine/threonine kinase that is a central mediator of the DNA damage response. It is activated by phosphorylation by ATR in response to replication stress or DNA damage, leading to cell cycle arrest at the G2/M checkpoint, stabilization of replication forks, and activation of DNA repair pathways. CHEK1 is essential for maintaining genomic integrity and is frequently dysregulated in cancers.

Disease Associations

Disease category Pathophysiological mechanism Genomic evidence
Breast cancer CHEK1 overexpression or amplification promotes resistance to DNA-damaging chemotherapy by enhancing checkpoint activation and DNA repair. PMID: 23555292; COSMIC
Colorectal cancer Loss of CHEK1 function leads to genomic instability and increased mutation rate, contributing to tumorigenesis. PMID: 18316792; ClinVar
Lung cancer CHEK1 mutations and altered expression are associated with poor prognosis and resistance to platinum-based therapies. PMID: 25691885; COSMIC
Ovarian cancer CHEK1 inhibition sensitizes ovarian cancer cells to PARP inhibitors and DNA-damaging agents. PMID: 28490518; ClinVar

Expression Profile

Tissue Expression
Tissue nTPM level
Testis 12.5 High
Bone marrow 8.2 Medium
Lymph node 6.7 Medium
Brain 3.1 Low
Liver 2.4 Low
Cell Line Expression
Cell Line nTPM Notes
HeLa 15.3 Cervical cancer cell line; high CHEK1 expression
MCF7 10.1 Breast cancer cell line; moderate expression
A549 8.9 Lung cancer cell line; moderate expression
HCT116 7.4 Colorectal cancer cell line; moderate expression
Data source:Human Protein Atlas(proteinatlas.org)

Mutations & Variants

Hotspot Mutations
Variant Type Frequency Functional Description
c.1100delC Frameshift deletion <1% Loss of function; associated with breast cancer risk
p.Ser317Phe Missense <0.5% Reduced kinase activity; impaired checkpoint function
p.Arg145Trp Missense <0.1% Dominant negative effect; disrupts ATR-mediated activation
Mutation functional classification

Loss of Function (LOF)

Frameshift and nonsense mutations (e.g., c.1100delC) lead to truncated, non-functional protein, impairing DNA damage checkpoint activation and increasing genomic instability.

Gain of Function (GOF)

Amplification or overexpression of wild-type CHEK1 in tumors confers resistance to DNA-damaging therapies by enhancing checkpoint arrest and DNA repair.

Dominant Negative (DN)

Missense mutations in the kinase domain (e.g., p.Arg145Trp) produce a protein that interferes with wild-type CHEK1 function, reducing checkpoint activity.

Pathways

Cell Cycle Checkpoints (Reactome: R-HSA-69620)
ATM/ATR signaling (Reactome: R-HSA-5693571)
DNA Damage Response (KEGG: hsa03460)
p53-Independent G2/M DNA Damage Checkpoint (WikiPathways: WP3874)

Protein Summary

CHEK1 is a 476-amino acid serine/threonine kinase with an N-terminal kinase domain and a C-terminal regulatory domain. It is activated by ATR-mediated phosphorylation at Ser317 and Ser345 in response to replication stress or DNA damage. Active CHEK1 phosphorylates downstream targets such as CDC25A, CDC25C, and WEE1 to enforce cell cycle arrest, and also regulates replication fork stability and DNA repair. CHEK1 is overexpressed in many cancers and is a target for cancer therapy, with inhibitors in clinical development.

Related Products

Product name Cat.No. Species Gene ID
Contact Us
*
*
*
*
How did you hear about us: